Objective: This study aimed to investigate the thetrapeutic effect and safety of topical Cyclosporine 0.1% in keratoconjunctivitis sicca associated with sjögrens syndrome. Patients and Method: Fifty patients with Sögrens symndrome associated keratocon-junctivits sicca were divided nito two groups. Topical Cyclosporine(CsA) or vehicle control was applied twice a for 3 months. The severity of symptoms, interpalpable Rose Bengal staining scores and Schirmer values were used as outcome evaluations.Results: Subjective symptoms improved in both groups at all intervals; however they did not show any statistical significant differece. The CsA group had a statistically significat improvement in Schirmer value in month 3, and staninig scores in month l and 3 compared with the control group. Conclusion: Topical Cyclosporine treatment may provide control of ocular surface in- flammation and reproduction of baseline tear secretion.(Tzu Chi Med J 2003; 15:85-89)